Search research articles
Contact Us
Filters
Showing results (21-30 of 61) with videos related to
Page
of 7
Sort By:
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
September 22, 2012
Does early improvement predict response to the fast-dissociating D₂ receptor antagonist JNJ-37822681 in patients with acute schizophrenia?
Ion-George Anghelescu, Luc Janssens, Justine Kent, et al.
Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists
|
August 9, 2013
Metabolic and body mass parameters after treatment with JNJ-37822681, a novel fast-dissociating D2 receptor antagonist, vs olanzapine in patients with schizophrenia
Ella J Daly, Justine M Kent, Luc Janssens, et al.
Scientific Reports
|
August 10, 2021
Minimally invasive quantification of cerebral P2X7R occupancy using dynamic [<sup>18</sup>F]JNJ-64413739 PET and MRA-driven image derived input function
Nathalie Mertens, Mark E Schmidt, Anja Hijzen, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
April 11, 2025
Efficacy, safety, and tolerability of JNJ-61393215 (tebideutorexant), a selective orexin-1 receptor antagonist, as adjunctive treatment for major depressive disorder with anxious distress: A double-blind, placebo-controlled, randomized phase 2a study
Mark E Schmidt, John A Moyer, Iva Kezic, et al.
Psychopharmacology
|
November 14, 2009
Dose-dependent effects of the CRF(1) receptor antagonist R317573 on regional brain activity in healthy male subjects
Mark E Schmidt, Randolph D Andrews, Peter van der Ark, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
January 30, 2026
Efficacy and safety of adjunctive treatment with the fatty acid amide hydrolase inhibitor JNJ-42165279 in participants with major depressive disorder with anxious distress: A double-blind, placebo-controlled, randomised study
Mark E Schmidt, Cynthia Gargano, Xianhuang Zhou, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
October 16, 2024
Efficacy and safety of JNJ-42165279, a fatty acid amide hydrolase inhibitor, in adolescents and adults with autism spectrum disorder: a randomized, phase 2, placebo-controlled study
Matthew E Klein, Abigail Bangerter, Robin J Halter, et al.
Alzheimer'S Research & Therapy
|
December 9, 2014
Imaging as a biomarker in drug discovery for Alzheimer's disease: is MRI a suitable technology?
Emilio Merlo Pich, Andreas Jeromin, Giovanni B Frisoni, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
May 12, 2005
A comparison of brain and serum pharmacokinetics of R-fluoxetine and racemic fluoxetine: A 19-F MRS study
Michael E Henry, Mark E Schmidt, John Hennen, et al.
Biological Psychiatry
|
August 30, 2003
Selective serotonin reuptake inhibitor discontinuation syndrome is associated with a rostral anterior cingulate choline metabolite decrease: a proton magnetic resonance spectroscopic imaging study
Marc J Kaufman, Michael E Henry, Blaise deB Frederick, et al.
Page
of 7
Search research articles
Search
Showing results (21-30 of 61) with videos related to
Sort By:
Page
of 7
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
September 22, 2012
Does early improvement predict response to the fast-dissociating D₂ receptor antagonist JNJ-37822681 in patients with acute schizophrenia?
Ion-George Anghelescu, Luc Janssens, Justine Kent, et al.
Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists
|
August 9, 2013
Metabolic and body mass parameters after treatment with JNJ-37822681, a novel fast-dissociating D2 receptor antagonist, vs olanzapine in patients with schizophrenia
Ella J Daly, Justine M Kent, Luc Janssens, et al.
Scientific Reports
|
August 10, 2021
Minimally invasive quantification of cerebral P2X7R occupancy using dynamic [<sup>18</sup>F]JNJ-64413739 PET and MRA-driven image derived input function
Nathalie Mertens, Mark E Schmidt, Anja Hijzen, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
April 11, 2025
Efficacy, safety, and tolerability of JNJ-61393215 (tebideutorexant), a selective orexin-1 receptor antagonist, as adjunctive treatment for major depressive disorder with anxious distress: A double-blind, placebo-controlled, randomized phase 2a study
Mark E Schmidt, John A Moyer, Iva Kezic, et al.
Psychopharmacology
|
November 14, 2009
Dose-dependent effects of the CRF(1) receptor antagonist R317573 on regional brain activity in healthy male subjects
Mark E Schmidt, Randolph D Andrews, Peter van der Ark, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
January 30, 2026
Efficacy and safety of adjunctive treatment with the fatty acid amide hydrolase inhibitor JNJ-42165279 in participants with major depressive disorder with anxious distress: A double-blind, placebo-controlled, randomised study
Mark E Schmidt, Cynthia Gargano, Xianhuang Zhou, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
October 16, 2024
Efficacy and safety of JNJ-42165279, a fatty acid amide hydrolase inhibitor, in adolescents and adults with autism spectrum disorder: a randomized, phase 2, placebo-controlled study
Matthew E Klein, Abigail Bangerter, Robin J Halter, et al.
Alzheimer'S Research & Therapy
|
December 9, 2014
Imaging as a biomarker in drug discovery for Alzheimer's disease: is MRI a suitable technology?
Emilio Merlo Pich, Andreas Jeromin, Giovanni B Frisoni, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
May 12, 2005
A comparison of brain and serum pharmacokinetics of R-fluoxetine and racemic fluoxetine: A 19-F MRS study
Michael E Henry, Mark E Schmidt, John Hennen, et al.
Biological Psychiatry
|
August 30, 2003
Selective serotonin reuptake inhibitor discontinuation syndrome is associated with a rostral anterior cingulate choline metabolite decrease: a proton magnetic resonance spectroscopic imaging study
Marc J Kaufman, Michael E Henry, Blaise deB Frederick, et al.
Page
of 7